Leerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28
Benzinga Newsdesk 1 month ago
NewsInitiationAnalyst RatingsPrice Target
Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.
Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.